Mature T-cell and NK-cell non-Hodgkin lymphoma

Researchers are testing whether combining two chemotherapy drugs, pralatrexate and romidepsin, is safe and effective for people with lymphoid cancers that have returned or stopped responding to treatment. The trial first finds the highest dose people can tolerate, then gives that…

This study tested a new drug combination (tolinapant plus decitabine/cedazuridine) in 33 adults with a rare, hard-to-treat blood cancer called peripheral T-cell lymphoma that had returned or not responded to prior treatment. The goal was to find a safe dose and see if the combina…

This early-stage study tested a new drug, PF-08046044/SGN-35C, in people with advanced lymphomas (Hodgkin and non-Hodgkin types) who had no other treatment options. The main goal was to check safety and find the right dose. The study was terminated early, so results are limited.

This study tested a new drug, PF-08046045, in 22 adults with advanced lymphomas (cancers of the immune system). The goal was to find a safe dose and check for side effects. The trial was stopped early, so results are limited.

This early-phase trial tested a combination of two immune-boosting drugs, relatlimab and nivolumab, in children and young adults with Hodgkin or non-Hodgkin lymphoma that had come back or not responded to treatment. The goal was to check safety, drug levels, and whether the tumor…

This early-phase study tested a new drug called PF-08046032, given alone or with another drug (sasanlimab), in adults with advanced lymphomas or solid tumors like lung cancer and melanoma. The trial aimed to check safety and find the right dose, but it was terminated early after …

This study tested a combination of two drugs, ixazomib and romidepsin, for people with a rare type of blood cancer called peripheral T-cell lymphoma that had returned or stopped responding to treatment. The trial was stopped early after enrolling only 11 participants, so the high…

This early-phase study tested the safety of a drug called tazemetostat in people with a type of blood cancer called peripheral T-cell lymphoma that had returned or stopped responding to other treatments. Only 6 participants were enrolled before the study was stopped early. The go…

This early-phase trial tested the drug ASTX660 in just 8 people with T-cell lymphoma that had returned or not responded to prior treatments. The study aimed to find a safe dose and check for side effects, but it was stopped early. Because it was so small and incomplete, we cannot…

This study tested a drug called selinexor combined with chemotherapy or another drug (tislelizumab) in people with relapsed or hard-to-treat T and NK cell lymphoma. The goal was to see if the combination was safe and could shrink tumors. The trial was stopped early, so results ar…

This early-phase trial tested a combination of two drugs, parsaclisib and chidamide, in 12 people with relapsed or refractory peripheral T-cell lymphoma. The goal was to find a safe dose and see if the combination could shrink tumors. The study was terminated early, so results ar…

This early-stage trial tested two drugs, isatuximab and cemiplimab, together in 58 people with relapsed or refractory lymphoma. The goal was to see if the combination was safe and could shrink tumors. The study was terminated early, so while some safety and response data were col…